RETINA MACULA INSTITUTE
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2007-01-01
- Employees
- -
- Market Cap
- -
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
Phase 2
Completed
- Conditions
- Proliferative Diabetic RetinopathyDiabetic Macular EdemaNon-proliferative Diabetic Retinopathy
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Retina Macula Institute
- Target Recruit Count
- 20
- Registration Number
- NCT01571232
- Locations
- 🇺🇸
Retina Macula Institute, Torrance, California, United States
Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2017-05-31
- Lead Sponsor
- Retina Macula Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01449682
- Locations
- 🇺🇸
Retina Macula Institute, Torrance, California, United States
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
Phase 2
Completed
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- Device: OCT, Multifocal ERG, Microperimetry
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2020-09-22
- Lead Sponsor
- Retina Macula Institute
- Target Recruit Count
- 91
- Registration Number
- NCT00764738
- Locations
- 🇺🇸
Retina Macula Institute, Torrance, California, United States
© Copyright 2025. All Rights Reserved by MedPath